ES2871483T3 - Sal hemisulfato del ácido 5,10-metilen-(6r)-tetrahidrofólico - Google Patents

Sal hemisulfato del ácido 5,10-metilen-(6r)-tetrahidrofólico Download PDF

Info

Publication number
ES2871483T3
ES2871483T3 ES17190279T ES17190279T ES2871483T3 ES 2871483 T3 ES2871483 T3 ES 2871483T3 ES 17190279 T ES17190279 T ES 17190279T ES 17190279 T ES17190279 T ES 17190279T ES 2871483 T3 ES2871483 T3 ES 2871483T3
Authority
ES
Spain
Prior art keywords
thf
hemisulfate salt
composition
hemisulfate
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17190279T
Other languages
English (en)
Spanish (es)
Inventor
Rudolf Moser
Viola Groehn
Thomas Ammann
Thomas Egger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck & Cie
Original Assignee
Merck & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Cie filed Critical Merck & Cie
Application granted granted Critical
Publication of ES2871483T3 publication Critical patent/ES2871483T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
    • C07D475/14—Benz [g] pteridines, e.g. riboflavin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ES17190279T 2013-08-14 2014-08-14 Sal hemisulfato del ácido 5,10-metilen-(6r)-tetrahidrofólico Active ES2871483T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13004050.4A EP2837631A1 (en) 2013-08-14 2013-08-14 New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid

Publications (1)

Publication Number Publication Date
ES2871483T3 true ES2871483T3 (es) 2021-10-29

Family

ID=48998397

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17190279T Active ES2871483T3 (es) 2013-08-14 2014-08-14 Sal hemisulfato del ácido 5,10-metilen-(6r)-tetrahidrofólico
ES14758102.9T Active ES2654474T3 (es) 2013-08-14 2014-08-14 Nueva sal estable del ácido 5,10-metilen-(6R)-tetrahidrofólico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14758102.9T Active ES2654474T3 (es) 2013-08-14 2014-08-14 Nueva sal estable del ácido 5,10-metilen-(6R)-tetrahidrofólico

Country Status (27)

Country Link
US (4) US20160185787A1 (enExample)
EP (3) EP2837631A1 (enExample)
JP (5) JP6617104B2 (enExample)
KR (2) KR102410373B1 (enExample)
CN (2) CN108096200A (enExample)
AU (2) AU2014307872B2 (enExample)
BR (2) BR122020002802B1 (enExample)
CA (1) CA2921178C (enExample)
CY (2) CY1119694T1 (enExample)
DK (2) DK3033344T3 (enExample)
EA (3) EA202091271A3 (enExample)
ES (2) ES2871483T3 (enExample)
HK (1) HK1256262A1 (enExample)
HR (2) HRP20171895T1 (enExample)
HU (2) HUE054504T2 (enExample)
IL (2) IL244069B (enExample)
LT (2) LT3033344T (enExample)
MX (2) MX360355B (enExample)
NO (1) NO3033344T3 (enExample)
NZ (2) NZ717825A (enExample)
PL (2) PL3033344T3 (enExample)
PT (2) PT3287460T (enExample)
RS (2) RS56910B1 (enExample)
SG (2) SG11201601016PA (enExample)
SI (2) SI3033344T1 (enExample)
WO (1) WO2015022407A1 (enExample)
ZA (1) ZA201509204B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
US10059710B2 (en) 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid
EP3446703A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
EP3446704A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
PT3668516T (pt) * 2017-08-16 2021-12-23 Merck Patent Gmbh Liofilizados estáveis que compreendem ácido 5,10-metileno-(6r)-tetra-hidrofólico e um ácido dicarboxílico
MX2020007009A (es) * 2018-01-05 2020-11-11 Isofol Medical Ab Metodos para tratar canceres colorrectales metastasicos y colorrectales.
KR20220152385A (ko) * 2020-03-30 2022-11-15 수미토모 케미칼 컴퍼니 리미티드 적층체
CN119325374A (zh) 2022-06-08 2025-01-17 默克专利股份有限公司 包含5,10-亚甲基-(6r)-四氢叶酸的稳定的冻干物
WO2023237483A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid
KR20250022144A (ko) 2022-06-08 2025-02-14 메르크 파텐트 게엠베하 5,10-메틸렌-(6R)-테트라히드로폴산 및 NACl을 포함하는 안정한 약학적 조성물
CN119343131A (zh) 2022-06-08 2025-01-21 默克专利股份有限公司 包含5,10-亚甲基-(6r)-四氢叶酸钠的浓缩溶液
WO2023237484A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2300505A (en) * 1940-10-31 1942-11-03 Bell Telephone Labor Inc Selective system
CA1215945A (en) 1983-03-20 1986-12-30 Bengt Gustavsson Fluid transfer system
DE3821875C1 (enExample) * 1988-06-29 1990-02-15 Eprova Ag, Forschungsinstitut, Schaffhausen, Ch
CH682664A5 (en) * 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
CH684644A5 (de) 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
HU226998B1 (en) * 2000-11-23 2010-04-28 Richter Gedeon Nyrt Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
CH697021A5 (de) 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
WO2007064968A2 (en) 2005-12-02 2007-06-07 Adventrx Pharmaceuticals, Inc. Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
AU2007336369B2 (en) * 2006-12-21 2013-01-17 F. Hoffmann-La Roche Ag Polymorphs of a mGluR5 receptor antagonist
JP5294968B2 (ja) 2009-05-01 2013-09-18 三星ダイヤモンド工業株式会社 スクライブヘッド及び該スクライブヘッドを用いたスクライブ装置
CN103998047A (zh) * 2011-10-19 2014-08-20 墨卡托医疗系统公司 局部调节组织和细胞以提高疗效包括肾去神经支配
EP2837766A1 (de) * 2013-08-14 2015-02-18 Sika Technology AG Verfahren zum Ausfüllen einer Fuge mit einem Kleb- und/oder Dichtstoff sowie System zum Ausfüllen einer Fuge mit einem Kleb- und/oder Dichtstoff
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
JP6971761B2 (ja) * 2017-10-11 2021-11-24 株式会社Ｉｈｉプラント タンクの構築方法

Also Published As

Publication number Publication date
JP6617104B2 (ja) 2019-12-04
JP6735321B2 (ja) 2020-08-05
IL269170B (en) 2020-09-30
EP2837631A1 (en) 2015-02-18
JP2019131579A (ja) 2019-08-08
CN105452250B (zh) 2018-02-27
HK1217018A1 (zh) 2016-12-16
PT3033344T (pt) 2018-01-03
CN105452250A (zh) 2016-03-30
NZ717825A (en) 2019-11-29
KR20160043054A (ko) 2016-04-20
HUE037615T2 (hu) 2018-09-28
HRP20210743T1 (hr) 2021-06-25
US12122783B2 (en) 2024-10-22
MX2016001834A (es) 2016-04-15
KR102439605B1 (ko) 2022-09-05
EA201892729A1 (ru) 2019-04-30
MX360355B (es) 2018-10-30
JP7396960B2 (ja) 2023-12-12
BR112016002770B1 (pt) 2022-12-06
RS56910B1 (sr) 2018-05-31
CN108096200A (zh) 2018-06-01
SG10201801179VA (en) 2018-03-28
ES2654474T3 (es) 2018-02-13
SG11201601016PA (en) 2016-03-30
EP3033344B1 (en) 2017-09-27
HUE054504T2 (hu) 2021-09-28
CY1119694T1 (el) 2018-04-04
DK3287460T3 (da) 2021-05-03
HK1256262A1 (zh) 2019-09-20
EP3287460A1 (en) 2018-02-28
EA201600172A1 (ru) 2016-07-29
IL269170A (en) 2019-11-28
AU2018278943B2 (en) 2019-12-05
NZ745811A (en) 2020-05-29
EP3033344A1 (en) 2016-06-22
NO3033344T3 (enExample) 2018-02-24
PL3033344T3 (pl) 2018-02-28
KR102410373B1 (ko) 2022-06-22
US20220024940A1 (en) 2022-01-27
JP6764501B2 (ja) 2020-09-30
EP3287460B1 (en) 2021-02-24
CA2921178C (en) 2020-12-08
DK3033344T3 (en) 2017-12-18
JP2020128410A (ja) 2020-08-27
LT3287460T (lt) 2021-07-26
ZA201509204B (en) 2017-04-26
EA032179B1 (ru) 2019-04-30
SI3033344T1 (en) 2018-01-31
JP7710356B2 (ja) 2025-07-18
KR20210038995A (ko) 2021-04-08
HRP20171895T1 (hr) 2018-01-26
CA2921178A1 (en) 2015-02-19
US20190106431A1 (en) 2019-04-11
MX382578B (es) 2025-03-13
IL244069B (en) 2019-09-26
PT3287460T (pt) 2021-05-27
IL244069A0 (en) 2016-04-21
US20240400574A1 (en) 2024-12-05
SI3287460T1 (sl) 2021-08-31
AU2014307872A1 (en) 2016-03-24
US20160185787A1 (en) 2016-06-30
EA202091271A2 (ru) 2020-09-30
JP2022024035A (ja) 2022-02-08
JP2018203763A (ja) 2018-12-27
WO2015022407A1 (en) 2015-02-19
PL3287460T3 (pl) 2021-07-19
JP2016528242A (ja) 2016-09-15
LT3033344T (lt) 2017-12-27
AU2018278943A1 (en) 2019-01-17
AU2014307872B2 (en) 2018-09-27
BR112016002770A2 (pt) 2017-08-01
RS61986B1 (sr) 2021-07-30
EA202091271A3 (ru) 2020-11-30
BR122020002802B1 (pt) 2022-11-29
CY1124076T1 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
US20240400574A1 (en) New stable salt of 5,10-methylene-(6r)-tetrahydrofolic acid
ES2975263T3 (es) Formas cristalinas de un compuesto triazolopirimidínico
ES2968174T3 (es) Forma en estado sólido de succinato de ribociclib
EP3023421A1 (en) Crystalline forms of afatinib dimaleate
ES2976576T3 (es) Formas cristalinas de un inhibidor de la fosfoinositida 3-quinasa (pi3k)
HK1217018B (en) Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid
EA041284B1 (ru) Способ получения лиофилизата гемисульфатной соли 5,10-метилен-(6r)-тетрагидрофолиевой кислоты
ES2372242B1 (es) Compuesto di{3,5-diacetil-1,2,4-triazol bis(4-ciclohexil tiosemicarbazonato)platino (ii)}, procedimiento de síntesis y su aplicación como fármaco antitumoral.